Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
REGULATORY
Three Ministers Agree on Off-Year Drug Price Revision in FY2025
Three Japanese Cabinet ministers on December 20 hammered out a basic policy for the next “off-year” drug price revision in FY2025, setting thresholds to define product coverage and putting an end to months-long debates over the issue. The policy was…
To read the full story
Related Article
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
REGULATORY
- US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
- MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
March 18, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…